Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients.
Pierantozzi
M
M
Pietroiusti
A
A
Galante
A
A
Sancesario
G
G
Lunardi
G
G
Fedele
E
E
Giacomini
P
P
Stanzione
P
P
D000284:Administration, Oral; D000368:Aged; D000704:Analysis of Variance; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D019540:Area Under Curve; D001682:Biological Availability; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D007980:Levodopa / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D009853:Omeprazole / Q000627:therapeutic use; D010300:Parkinson Disease / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D007980:Levodopa; D009853:Omeprazole